west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "许东" 6 results
  • 直肠息肉术后发生腹膜后积气及感染 1 例报道

    Release date:2017-04-18 03:08 Export PDF Favorites Scan
  • Ultrasound Guided Combined with Laparoscopic Microwave Ablation in Treatment for Special Site Liver Cancer

    Objective To explore the clinical value and experience of ultrasound guided combined with laparoscopic microwave ablation in treatment for special site liver cancer.Methods The clinical data of 9 patients with liver cancer treated by ultrasound guided combined with laparoscopic microwave ablation in our hospital from February 2008 to October 2010 were analyzed retrospectively.Results There were 6 cases of primary liver cancer, 3 cases of metastatic hepatic carcinoma. Eight cases of multiple tumors, 1 case of single tumor.There were one or more lesions invading liver capsular,a total of 13 lesions in all the patients. Among them,6 lesions located in diaphragm, 3 closed to bowel, 2 neared stomach,1 located in gallbladder bed and 1 in hilar.No serious complications and no death happened during operation.The following-up time was (9.2±4.7) months (4 to 18 months), there were 2 lesions of part residual, including 1 case of microwave ablation again,1 case of percutaneous ethanol ablation, and 11 lesions of complete ablation (84.6%,11/13) 1 month after operation by CT examination.Four cases recurred 3 months after operation by CT examination, including 2 cases of microwave ablation again,1 case of percutaneous ethanol ablation,1 patient with pulmonary metastasis and giving up treatment,1 patient with poor liver function and died of liver failure 6 months after operation;1 patient with multiple lesions died of brain metastases 10 months after operation; the rest were still alive.Conclusions Ultrasound guided combined with laparoscopic microwave ablation is a safe and effective method in the treatment for special site liver cancer,the curative effect is good and worth of spread.

    Release date:2016-09-08 10:36 Export PDF Favorites Scan
  • Experience about Transumbilical Single-Port Laparoscopic Appendectomy by Using Traditional Instrument

    目的 总结经脐单切口腹腔镜阑尾切除术的技术要点。方法 回顾性分析2012年1月至12月期间中国医科大学附属第四医院收治并行经脐单切口腹腔镜阑尾切除术的55例阑尾炎患者的临床资料。结果 54例患者手术均获成功,1例患者因腹膜后阑尾而中转为3孔法。手术时间为(40.6±12.3) min (35~90min),住院时间为(4.5±1.3) d (3~6d),住院费用为(1.2±0.3)万元(0.8~1.5万元),术后均无并发症发生。术后49例患者获访,随访时间为1~6个月,平均4.8个月。术后患者均恢复良好,脐部瘢痕不明显,美容效果较满意。结论 采用通用器械行经脐单切口腹腔镜阑尾切除术安全、可行,美容效果较佳。

    Release date:2016-09-08 10:34 Export PDF Favorites Scan
  • 目的 探讨自制双套管持续冲洗负压引流治疗胰腺术后胰瘘的效果。 方法 回顾性分析2008 年 8 月至2014 年3 月期间于笔者所在医院接受自制双套管持续冲洗负压引流治疗的12 例胰瘘患者的临床资料,总 结效果。 结果 12 例患者均接受双套管持续冲洗负压引流治疗,治疗期间引流管若有堵塞,可拔出体外清理。所 有患者均于拔管后治愈。更换双套管早期(1 ~ 3 d)患者发热等感染症状明显缓解,引流10 ~ 22 d 后引流量逐渐 减少。出院后所有患者均获访6 个月,患者恢复良好,胰瘘部位包裹吸收,无并发症发生。 结论 自制双套管持续 冲洗负压引流治疗胰腺术后胰瘘的效果满意,安全可行。

    Release date: Export PDF Favorites Scan
  • Postoperative Survival Analysis of Patients with Mini Pathological N2 Non-small Cell Lung Cancer

    ObjectiveTo explore prognostic factors of non-small cell lung cancer(NSCLC)patients with preoperative clinical N0 staging but unexpected postoperative pathological N2 staging (cN0-pN2). MethodsClinical data of NSCLC patients with cN0-pN2 after radical lung cancer resection in Huashan Hospital Affiliated to Fudan University from January 2006 to December 2010 were retrospectively analyzed. Survival information was collected through followup, and follow-up expired on December 31, 2012. Prognostic factors of NSCLC patients with cN0-pN2 were analyzed using Cox proportional-hazard regression. ResultsA total of 263 patients were enrolled in this study. The followup rate was 91.63%. Overall 1-year, 3-year and 5-year survival rate was 94.6%, 55.2% and 26.3%, respectively. Videoassisted thoracoscopic surgery (VATS, P=0.017, RR=0.659, 95%CI 0.469-0.927), multiple stations of mediastinal lymph node metastases (P=0.003, RR=1.605, 95%CI 1.180-2.183), no adjuvant chemotherapy(P=0.012, RR=1.576, 95%CI 1.105-2.246) were independent predictive factors for NSCLC patients with cN0-pN2. For patients with single station N2, median survival after VATS was significantly longer than that after open thoracotomy (48.55 months vs. 37.34 months, P=0.018). For patients with multiple stations of mediastinal lymph node metastases, median survival without any adjuvant chemotherapy was significantly shorter than that after adjuvant chemotherapy (20.32 months vs. 31.55 months, P=0.001). ConclusionPrognosis of NSCLC patients with cN0-pN2 is related to operational methods, adjuvant chemotherapy and station number of mediastinal lymph node metastasis. Patients with single station of mediastinal lymph node metastasis are more likely to benefit from VATS while patients with multiple stations of mediastinal lymph node metastases are more likely to benefit from adjuvant chemotherapy.

    Release date: Export PDF Favorites Scan
  • Clinical pathological characteristics and prognosis of 468 thymoma patients

    ObjectiveTo assess the correlation of WHO pathological classification and Masaoka stage of thymomas with its prognosis.MethodsA total of 468 patients with thymomas who received surgeries during 2009-2019 in Huashan Hospital, Fudan University, were collected. There were 234 males and 234 females with an average age of 21-83 (49.6±18.7) years. A total of 132 patients underwent video-assisted thoracic surgery (VATS) and 336 patients underwent thymectomy with median sternal incision. The follow-up time was 5.7±2.8 years. The clinical data of the patients were analyzed.ResultsThe amount of intraoperative bleeding was 178.3±133.5 mL in the median sternal incision group, and 164.8±184.1 mL in the VATS group (P=0.537). The operative time was 3.3±0.7 h in the median sternal incision group and 3.4±1.2 h in the VATS group (P=0.376). Postoperative active bleeding, phrenic nerve injury and chylothorax complications occurred in 8 patients, 9 patients and 1 patient in the VATS group, respectively, and 37 patients, 31 patients and 7 patients in the median sternal incision group, respectively. There was no statistical difference between the two groups (P=0.102, 0.402, 0.320). The 5-year cumulative progression free survival (PFS) rates of patients with WHO type A, AB, B1, B2, B3 and C thymomas were 100.0%, 100.0%, 95.7%, 81.4%, 67.5% and 50.0%, respectively (P<0.001). The 5-year PFS rates of patients with Masaoka stageⅠ-Ⅳ thymomas were 96.1%, 89.2%, 68.6% and 19.3%, respectively (P<0.001). The 5-year PFS rate was 87.3% in patients with myasthenia gravis (MG) and 78.2% in patients without MG (P<0.001). The 5-year PFS rates of patients with different surgeries were 82.4% and 83.8%, respectively (P=0.904). ConclusionWHO pathological classification and Masaoka stage have significant clinical prognosis suggestive effect. Thymoma patients combined with MG have better prognosis, which suggests early diagnosis and treatment of thymoma are important.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content